Polaryx Therapeutics, Inc.
Data quality: 83%
PLYX
NASDAQ
Manufacturing
Chemicals
$5.68
▼
$0.08
(-1.39%)
Mkt Cap: 265.27 M
Price
$5.84
Mkt Cap
265.27 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—
Quick Summary
Key Takeaways
Negative free cash flow of -3.94 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-196.82%
Below sector avg (-54.44%)
ROIC-135.35%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio8.55
Interest CoverageN/A
Valuation
PE (TTM)
-29.52
Below sector avg (-1.49)
P/B Ratio58.11
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1385 peers)
Peer Comparison
vs Manufacturing sector median (1385 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -29.5 | -1.5 |
| P/B | 58.1 | 1.6 |
| ROE % | -196.8 | -54.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.9 |
| D/E | — | 0.3 |
Analyst Price Target
1 analyst
Strong Buy
Current
$5.68
Target
$10.00
$10.00
$10.00
$10.00
Forecast
Forward EPS
-$0.28
Est. Revenue
0.0
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2027 |
-$0.28
-$0.28 – -$0.28
|
0.0 | 1 |
| FY2026 |
-$0.12
-$0.12 – -$0.12
|
0.0 | 1 |
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| 2026 Q2 |
-$0.03
-$0.03 – -$0.03
|
0.0 | 1 |
| 2026 Q1 |
-$0.03
-$0.03 – -$0.03
|
0.0 | 1 |
Earnings Surprises
Last 1 quarter
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| Q42025 | -$0.02 | -$0.16 | -700.0% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -8.99 M |
| ROE | -196.82% | ROA | -173.79% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -3.94 M |
| ROIC | -135.35% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 8.55 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 4.57 M | Tangible Book Value | 4.57 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -29.52 | Forward P/E | N/A |
| P/B Ratio | 58.11 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -1.49% | ||
| Market Cap | 265.27 M | Enterprise Value | 260.12 M |
| Per Share | |||
| EPS (Diluted TTM) | -0.20 | Revenue / Share | N/A |
| FCF / Share | -0.09 | OCF / Share | -0.09 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 43.90% |
| SBC-Adj. FCF | -8.67 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 |
|---|---|
| Revenue | — |
| Net Income | -8.99 M |
| EPS (Diluted) | -0.20 |
| Gross Profit | — |
| Operating Income | -7.82 M |
| EBITDA | — |
| R&D Expenses | 6.27 M |
| SG&A Expenses | — |
| D&A | — |
| Interest Expense | — |
| Income Tax | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 |
|---|---|
| Total Assets | 5.17 M |
| Total Liabilities | 605,000.0 |
| Shareholders' Equity | 4.57 M |
| Total Debt | — |
| Cash & Equivalents | 5.14 M |
| Current Assets | 5.17 M |
| Current Liabilities | 605,000.0 |
{"event":"ticker_viewed","properties":{"ticker":"PLYX","listing_kind":"stock","pathname":"/stocks/plyx","exchange":"NASDAQ","country":"US"}}